Loading...

The current price of ENLV is 0.861 USD — it has decreased -7.32 % in the last trading day.
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Wall Street analysts forecast ENLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENLV is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Enlivex Therapeutics Ltd revenue for the last quarter amounts to 0.00 USD, decreased % YoY.
Enlivex Therapeutics Ltd. EPS for the last quarter amounts to -0.09 USD, decreased -25.00 % YoY.
Enlivex Therapeutics Ltd (ENLV) has 36 emplpoyees as of December 16 2025.
Today ENLV has the market capitalization of 203.45M USD.